IBD Clinical Trials 2024

IBD Clinical Trials 2024

IBD research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in irritable bowel disorder clinical trials today.

Trials for Crohn's Disease Patients

Trials for Inflammatory Bowel Disease Patients

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to ibd

What are the top hospitals conducting ibd research?

When it comes to cutting-edge clinical trials focused on inflammatory bowel disease (IBD), several top hospitals are leading the way. Located in Cincinnati, the Cincinnati Children's Hospital Medical Center is dedicated to finding new treatments and therapies for this condition. Currently, they have two active IBD trials underway, representing their commitment to pushing the boundaries of medical research. Similarly, in Pittsburgh at the University of Pittsburgh Medical Center, researchers are conducting two ongoing IBD trials with a similar goal of improving outcomes for patients with this chronic inflammatory condition.

Moving eastward to Boston's prestigious Brigham and Women's Hospital, we find another institution actively engaged in advancing our understanding of IBD through two ongoing clinical trials. These hospitals serve as beacons of hope for those living with IBD by offering innovative treatment options and contributing valuable knowledge to the medical community.

North of the border in Toronto at Mount Sinai Hospital lies another hub of research excellence where scientists tirelessly investigate new approaches for managing IBD. With two active clinical trials centered around this complex condition, they strive to make significant strides towards better patient care.

Notably making an impact from Edmonton is the University of Alberta Hospital, which has taken up a crucial role in combating IBD. Although currently focusing on one active trial related to this challenging gastrointestinal illness that affects millions worldwide; their dedication speaks volumes about their commitment towards relieving those suffering from its debilitating symptoms.

These esteemed institutions represent promising avenues for future breakthroughs that could transform the lives of individuals grappling with IBD across North America and beyond. Through pioneering research initiatives like these, we move closer than ever before toward uncovering effective treatments and ultimately working toward a cure - instilling optimism among both patients and healthcare professionals alike

Which are the best cities for ibd clinical trials?

When it comes to clinical trials for IBD, several cities lead the way in research and development. Boston, Massachusetts; New york, New York; Cincinnati, Ohio; Edmonton, Alberta; and Palo Alto, California all have active trials focusing on different aspects of IBD treatment. These trials explore a range of interventions such as Vitamin D3 supplementation, high definition colonoscopy procedures, remote monitoring techniques, fucosyllactose supplementation, plant-based fasting-mimicking diets and more. With their commitment to advancing knowledge about IBD management and treatment options through clinical trials, these cities provide opportunities for individuals seeking innovative approaches to managing this condition.

Which are the top treatments for ibd being explored in clinical trials?

Clinical trials are paving the way for innovative treatments in the field of inflammatory bowel disease (IBD). One promising contender is vedolizumab, which has shown significant potential with several ongoing trials. Another notable option being explored is ustekinumab, demonstrating its effectiveness in managing IBD through clinical studies. Additionally, tofacitinib showcases promise as a therapeutic approach for IBD patients based on current research findings. These top treatments offer hope and progress towards improving the lives of individuals affected by IBD.

What are the most recent clinical trials for ibd?

Exciting advancements are being made in the field of inflammatory bowel disease (IBD) through recent clinical trials. One notable trial investigates the potential benefits of Aspirin 81Mg Ec Tab for IBD patients, with promising results emerging from Phase 3 studies. Additionally, Methylprednisolone has shown promise as a treatment option during Phase 1 trials for individuals with IBD. Another significant trial focuses on Bezlotoxumab and its effects on IBD patients, showing encouraging outcomes during Phase 2 research. These groundbreaking studies offer hope for improved management and treatment options for those living with IBD.

What ibd clinical trials were recently completed?

Recently completed clinical trials in the field of inflammatory bowel disease (IBD) have made significant strides in advancing treatment options for patients. Notably, a trial sponsored by AbbVie Inc., investigating the effectiveness of risankizumab for Crohn's disease and ulcerative colitis, concluded successfully. Additionally, Janssen Research & Development recently completed an important trial evaluating ustekinumab as a potential therapy for IBD. These recent advancements highlight the ongoing commitment to finding innovative approaches to managing and mitigating the impact of IBD on patients' lives.